1.0	Bristol-Myers	announce	licence agreement	MISC	0
1.0	post-launch	will share commercialisation expense on	global basis exclude Japan	0	LOCATION
1.0	company	plan	file	0	0
1.0	post-launch	will share commercialisation expense on	basis exclude Japan	0	LOCATION
1.0	company	have	strategy	O	O
1.0	2008	have	half	DATE	DATE
1.0	Bristol-Myers	be in	line also	0	0
1.0	Saxagliptin	be in	phase iii development	0	0
1.0	Bristol-Myers	announce licence agreement at_time	last month	MISC	DATE
1.0	drug	announce collaboration worth on	Thursday	0	DATE
1.0	anglo-swedish drug	announce collaboration worth up on	Thursday	0	DATE
1.0	giant AstraZeneca	will make	upfront payment	ORGANIZATION	0
1.0	giant AstraZeneca	will make	payment of 100 million dollar	ORGANIZATION	MONEY
1.0	giant AstraZeneca	will make payment under	term	ORGANIZATION	0
1.0	post-launch	will share equally	commercialisation expense	0	0
1.0	company	file in	half of 2008	0	DATE
1.0	post-launch	will share commercialisation expense on	basis	0	0
1.0	additional development cost	will	will share equally	0	0
1.0	David Brennan	executive of	anglo-swedish group	PERSON	0
1.0	drug	announce	collaboration worth	0	0
1.0	Dapagliflozin	be in	phase iib development	0	0
1.0	drug	develop	two diabetes compound	0	NUMBER
1.0	Bristol-Myers	be in	line	0	0
1.0	Bristol-Myers chief executive Jim Cornelius meanwhile	have	company	O	O
1.0	post-launch	will share commercialisation expense equally on	basis	0	0
1.0	company	plan	file for US approval in half of 2008	0	LOCATION
1.0	post-launch	will share commercialisation expense on	global basis	0	0
1.0	Bristol-Myers	announce licence agreement for	saxagliptin	MISC	0
1.0	Saxagliptin	have	externalisation strategy	O	O
1.0	much sugar	be in	they blood	0	0
1.0	company	plan	file for US regulatory approval in half of 2008	0	LOCATION
1.0	company	plan	file for US regulatory approval in half	0	LOCATION
1.0	company	plan	file for US regulatory approval in first half of 2008	0	DATE
1.0	company	file for	US regulatory approval	0	LOCATION
1.0	post-launch	will share commercialisation expense equally on	basis exclude Japan	0	LOCATION
1.0	Bristol-Myers	announce licence agreement at_time	month	MISC	DATE
1.0	company	plan	file in half of 2008	0	DATE
1.0	giant AstraZeneca	will make	upfront payment of 100 million dollar	ORGANIZATION	MONEY
1.0	Bristol-Myers	announce licence agreement with	Otsuka Pharmaceutical	MISC	PERSON
1.0	company	file in	first half of 2008	0	DATE
1.0	late stage compound	be in	area of high unmet medical need	0	0
1.0	development costs	have	majority	O	O
1.0	post-launch	will share	commercialisation expense	0	0
1.0	company	plan	file for US approval	0	LOCATION
1.0	group	have	executive	O	O
1.0	Diabetes	have	Sufferers	O	O
1.0	dollars	have	payment	O	MONEY
1.0	compounds	have	marketing strategy	O	O
1.0	collaboration agreement	be worldwide for	Japan	0	LOCATION
1.0	drug	announce collaboration worth up on	Thursday	0	DATE
1.0	giant AstraZeneca	will fund	majority	ORGANIZATION	0
1.0	need	have	area	O	O
1.0	drug	announce up	collaboration worth	0	0
1.0	giant AstraZeneca	will fund majority until	2009	ORGANIZATION	DATE
1.0	sufferer	have	too much sugar	0	0
1.0	giant AstraZeneca	will fund	majority of development cost	ORGANIZATION	0
1.0	company	plan	file in first half	0	DATE
1.0	sufferer	have	much sugar	0	0
1.0	Bristol-Myers Squibb	be group of	US	ORGANIZATION	LOCATION
1.0	company	plan	file for US regulatory approval in first half	0	DATE
1.0	anglo-swedish drug	develop	two diabetes compound	0	NUMBER
1.0	company	file in	first half	0	DATE
1.0	additional development cost	will	will share	0	0
1.0	company	plan	file in half	0	DATE
1.0	Bristol-Myers	announce	exclusive licence agreement	MISC	0
1.0	anglo-swedish drug	announce collaboration worth on	Thursday	0	DATE
1.0	company	with	corporate strategy	0	0
1.0	company	plan	file for US approval in first half of 2008	0	DATE
1.0	epidemic proportion	be in	many region	0	0
1.0	post-launch	will share commercialisation expense equally on	global basis exclude Japan	0	LOCATION
1.0	company	plan	file in first half of 2008	0	DATE
1.0	Sufferers of diabetes	have	blood	O	O
1.0	deal	have	terms	O	O
1.0	Saxagliptin	be in	currently phase iii development	0	DATE
1.0	giant AstraZeneca	will make payment under	term of deal	ORGANIZATION	0
1.0	company	plan	file for US approval in first half	0	DATE
1.0	sufferer	have	sugar	0	0
1.0	company	file in	half	0	DATE
1.0	anglo-swedish drug	announce up	collaboration worth	0	0
1.0	post-launch	will share commercialisation expense equally on	global basis	0	0
1.0	company	plan	file for US approval in half	0	LOCATION
1.0	giant AstraZeneca	will make	payment	ORGANIZATION	0
1.0	company	file for	US approval	0	LOCATION
1.0	company	plan	file for US regulatory approval	0	LOCATION
1.0	Bristol-Myers Squibb	be to	US	ORGANIZATION	LOCATION
1.0	interest	have	area	O	O
1.0	anglo-swedish drug	announce	collaboration worth	0	0
